PPARs and Xenobiotic-Induced Adverse Effects: Relevance to Human HealthView this Special Issue
Review Article | Open Access
Michung Yoon, "PPAR in Obesity: Sex Difference and Estrogen Involvement", PPAR Research, vol. 2010, Article ID 584296, 16 pages, 2010. https://doi.org/10.1155/2010/584296
PPAR in Obesity: Sex Difference and Estrogen Involvement
Peroxisome proliferator-activated receptor (PPAR) is a member of the steroid hormone receptor superfamily and is well known to act as the molecular target for lipid-lowering drugs of the fibrate family. At the molecular level, PPAR regulates the transcription of a number of genes critical for lipid and lipoprotein metabolism. PPAR activators are further shown to reduce body weight gain and adiposity, at least in part, due to the increase of hepatic fatty acid oxidation and the decrease in levels of circulating triglycerides responsible for adipose cell hypertrophy and hyperplasia. However, these effects of the PPAR ligand fenofibrate on obesity are regulated with sexual dimorphism and seem to be influenced by the presence of functioning ovaries, suggesting the involvement of ovarian steroids in the control of obesity by PPAR. In female ovariectomized mice, 17-estradiol inhibits the actions of fenofibrate on obesity through its suppressive effects on the expression of PPAR target genes, and these processes may be mediated by inhibiting the coactivator recruitment of PPAR. Thus, it is likely that PPAR functions on obesity may be enhanced in estrogen-deficient states.
Obesity is the result of an energy imbalance caused by an increased ratio of caloric intake to energy expenditure. In conjunction with obesity, related metabolic disorders such as dyslipidemia, atherosclerosis, and type 2 diabetes have become global health problems. The peroxisome proliferator-activated receptors (PPARs) have been the subject of intense investigation and considerable pharmacological research due to the fact that they are involved in the improvement of these chronic diseases. Three PPAR isotypes have been identified: PPAR PPAR and PPAR each with different ligand specificity, very distinct tissue distributions, and different biological functions.
Among the three subtypes, PPAR is expressed predominantly in tissues that have a high level of fatty acid (FA) catabolism such as liver, heart, and muscle [1–3]. PPAR regulates the expression of a large number of genes that affect lipid and lipoprotein metabolism [4–7]. PPAR ligands fibrates have been used for the treatment of dyslipidemia due to their ability to lower plasma triglyceride levels and elevate HDL cholesterol levels. PPAR is also thought to be involved in energy metabolism. Since PPAR ligands fibrates stimulate hepatic FA oxidation and thus reduce the levels of plasma triglycerides responsible for adipose cell hypertrophy and hyperplasia, PPAR may be important in the control of adiposity and body weight due to its ability to regulate an overall energy balance. This notion is supported by findings showing that PPAR-deficient mice exhibited abnormalities in triglyceride and cholesterol metabolism and became obese with age . Furthermore, several studies have suggested that fibrates can modulate body weight and adiposity in experimental animal models, such as fatty Zucker rats, high fat-fed C57BL/6 mice, and high fat-fed obese rats [9–11].
Energy balance seems to be influenced by gonadal sex steroids . Female sex steroid hormones have been the subject of intense investigation over the last several decades based on the role that these ovarian hormones play in regulating food intake, body weight, and lipid metabolism. For example, ovariectomized (OVX) animals and postmenopausal women show increased food intake, body weight, and adipose tissue mass, as well as decreased FA oxidation and triglyceride lipolysis, indicating the involvement of gonadal steroids in the modulation of obesity [13–16]. Several lines of study show that ovarian steroids, in particular estrogens, can affect obesity and the related disorders of dyslipidemia, type 2 diabetes, and cardiovascular disease (CVD) . Estrogen insufficiency is known to be largely responsible for increased adiposity and circulating lipids in OVX rodents because such animals do not display obesity, adiposity, and lipid disorders when they are administered exogenous estrogens [17–19]. Moreover, my previous results demonstrated that fenofibrate reduced body weight and white adipose tissue (WAT) mass in male and female OVX mice [20–23]. Although the administration of 17-estradiol (E2) or fenofibrate alone effectively reduces body weight gain and WAT mass in female OVX mice, fenofibrate treatment does not prevent gains in body weight and WAT mass in the presence of ovaries. Interestingly, there are data indicating that PPAR/RXR heterodimers are capable of binding to estrogen response elements (EREs), and PPAR and estrogen receptors (ERs) share cofactors [24–28], suggesting that signal cross-talk may exist between PPAR and ERs in the control of obesity.
Based on my published results showing the fenofibrate functions on obesity during various conditions, this paper will focus on the differential regulation of PPAR on obesity by sex differences and the interaction of PPAR and ERs in the regulation of obesity.
2. General Aspects of PPAR and ERs
2.1. PPAR and ERs as Nuclear Hormone Receptors
Both PPAR and ERs belong to the nuclear hormone receptor superfamily, which has a typical structure consisting of six functional domains, A/B, C, D, and E/F (Figure 1) [29–31]. The amino-terminal A/B domain contains a ligand-independent activation function-1 (AF-1). The C or DNA binding domain (DBD) contains the structure of the two zinc fingers and α-helical DNA motifs. The DBD directs nuclear receptors to the hormone response elements (HREs) of target genes. The D region is a highly flexible hinge region and may be involved in protein-protein interactions, such as receptor dimerization and efficient binding of DBD to HREs. The E/F domain is responsible for ligand-binding and is thus named the ligand binding domain (LBD). The interaction of nuclear receptors with their ligands induces conformational changes that include the AF-2 ligand-dependent activation domain, which is located in the C-terminal -helix. AF-2 regulates ligand-dependent transactivation, recruitment of coactivators, and release of corepressors. In addition, AF-2 is also important for receptor dimerization.
Molecular signaling of PPARα and ERs functions is similar [34–37]. In the unliganded or antagonist-bound state, they are associated with corepressor proteins such as nuclear receptor corepressor (NCoR) or silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) (Figure 2(a)). After binding within the LBD, PPARα ligands induce heterodimerization with retinoid X receptor (RXR) and the subsequent interaction with coactivators like CREB-binding protein (CBP) or steroid receptor coactivators, followed by binding to PPAR response elements (PPREs) within target gene promoters (Figure 2(b)). Similarly, ligand-activated ERs bind to their half-site-containing EREs as homodimers following the recruitment of coactivators. Importantly, PPAR shares a similar pool of cofactors with ERs which provides a basis for mutual interactions between these receptors [34, 35].
(a) Repression: no ligand or antagonist binding
(b) Activation: agonist binding
PPAR was the first PPAR to be identified by Issemann and Green in 1990, and human PPAR was cloned by Sher et al. in 1993 [1, 38]. PPARα is predominantly expressed in tissues with high rates for mitochondrial and peroxisomal FA catabolism such as liver, brown adipose tissue (BAT), heart, skeletal muscle, kidney, and intestinal mucosa [1–3]. Significant amounts of PPAR are present in different immunological and vascular wall cell types [39, 40].
PPAR acts as a ligand-activated transcription factor. PPAR mediates the physiological and pharmacological signaling of synthetic or endogenous PPAR ligands. FAs and FA-derived compounds are natural ligands for PPAR. Modified FAs, conjugated FAs, oxidized phospholipids, and FA-derived eicosanoids such as 8-S-hydroxytetraenoic acid and leukotriene B4 activate PPAR . Synthetic compounds can also activate PPAR. These compounds include carbaprostacyclin, nonsteroidal anti-inflammatory drugs, pirinixic acid (also known as Wy14,643), phthalate ester plasticizers, and hypolipidemic drugs fibrates . Of the currently used fibrates, fenofibrate, gemfibrozil, clofibrate, and ciprofibrate preferentially activate PPAR whereas bezafibrate activates all three PPARs. Novel PPAR dual agonists and PPAR pan agonists with PPAR selective modulator activity are under development as drug candidates [42, 43].
PPAR regulates the expression of a number of genes critical for lipid and lipoprotein metabolism, thereby leading to lipid homeostasis. Ligand-bound PPAR heterodimerizes with RXR and binds to direct repeat PPREs in the promoter region of target genes (Figure 3(a)). PPAR target genes include those involved in the hydrolysis of plasma triglycerides, FA uptake and binding, and FA –oxidation (Table 1). Genes involved in the HDL metabolism are also regulated by PPAR. The activation of PPAR target genes therefore promotes increased -oxidation of FAs, as well as the decrease in high circulating triglyceride levels and increased high HDL cholesterol levels, leading to lipid homeostasis.
In addition to PPAR regulation of genes for lipid and lipoprotein metabolism, PPAR regulates the expression of uncoupling proteins (UCPs), which contain PPRE in their promoters. PPAR activators increase the mRNA levels of UCP1 in BAT, UCP2 in liver, and UCP3 in skeletal muscle. UCP1 regulates energy expenditure through thermogenesis. Reductions in body weight and adiposity by fenofibrate are associated with elevation of hepatic UCP2 expression . Transgenic mice overexpressing UCP3 in their skeletal muscle exhibit increased FA oxidation and are resistant to diet-induced obesity. Thus, PPAR may be involved in energy balance and obesity by regulating UCPs .
In addition to the important roles of PPAR in FA oxidation in liver and skeletal muscle, PPAR activators may affect adipose tissue metabolism. For example, administration of bezafibrate, a typical PPAR activator, leads to dedifferentiation of adipocytes into preadipocyte-like cells through the activation of genes involved in both mitochondrial and peroxisomal -oxidation . The PPAR ligand GI259578A decreases the mean size of adipocytes in WAT . This is supported by my recent report that fenofibrate stimulates FA –oxidation in both epididymal adipose tissue and differentiated 3T3-L1 adipocytes .
PPAR may be involved in the regulation of energy balance through fat catabolism. Since fenofibrate increases hepatic FA oxidation and thus decreases the levels of plasma triglycerides responsible for adipose cell hypertrophy and hyperplasia, it may inhibit an increase in body weight. This is supported by a report that PPAR-deficient mice showed abnormal triglyceride and cholesterol metabolism and became obese with age . Expression of PPAR and FA oxidative PPAR target genes is suppressed in obese mice . Many studies show that fenofibrate can modulate body weight in animal models of diabetes, obesity, and insulin resistance although another known PPAR stimulator perfluorooctanoic acid induces overweight at low doses in intact female mice [9–11, 50].
PPAR also regulates insulin resistance and diabetes due to visceral obesity. Fenofibrate prevents adipocyte hypertrophy and insulin resistance by increasing FA -oxidation and intracellular lipolysis from visceral adipose tissue, showing that PPAR may be one of the major factors leading to decreased adipocyte size and improved insulin sensitivity . Moreover, PPAR agonist treatment has been reported to improve pancreatic -cell function in insulin-resistant rodents and the adaptive response of the pancreatic -cell function to pathological conditions, such as obesity [51, 52]. In addition, PPAR agonists, including fibrates, normalize atherogenic lipid profile, as well as several cardiovascular risk markers .
Like PPAR ERs function as ligand-dependent transcription factors belonging to members of the nuclear hormone receptor family. Two major ERs (ER and ER) mediate the physiological and pharmacological signals of natural or synthetic ER activators. Upon estrogen binding, ERs are activated and act as transcriptional modulators by binding to palindromic EREs in the promoter region of target genes (Figure 3(b)) [54, 55]. ERs are also activated by specific synthetic ligands such as raloxifene, tamoxifen, and the ER-specific ligand diarylpropionitrile. ER is mainly expressed in the female reproductive system such as ovary, uterus, pituitary, and mammary glands but is also present in the hypothalamus, brain, bone, liver, WAT, skeletal muscle, and the cardiovascular system [56–58]. ER is expressed in many tissues including skeletal muscle, WAT, BAT, prostate, salivary glands, testis, ovary, vascular endothelium, the immune system, and certain neurons of the central and peripheral nervous system [59, 60].
The natural forms of estrogens are E2, estrone, and estriol. E2 potently activates ER-mediated transcriptional activity to a greater extent than estrone or estriol. E2 has been considered one of the most important hormones in female physiology and reproduction for a long period. However, we now know that E2 also plays a protective role in a variety of pathophysiological states, such as obesity, cardiovascular disease, hyperlipidemia, diabetes, osteoporosis, and cancer in both men and women .
E2 is involved in the regulation of adiposity and obesity, and visceral fat varies inversely with E2 levels . Accumulation of visceral fat occurs in females when E2 levels become sufficiently low. In rodents, ovariectomy leads to weight gain primarily in the form of adipose tissue, which is reversed by physiologic E2 replacement [12, 63–65]. Loss of circulating E2 is associated with an increase in adiposity during menopause whereas postmenopausal women who receive E2 replacement therapy do not display the characteristic abdominal weight gain pattern usually associated with menopause [13–15]. Aromatase deficiency, during which E2 is not produced, results in the development of adiposity and obesity . Furthermore, ER deficiency increased adipose tissue in both male and female mice, consistent with other reports linking estrogen with body weight regulation and adipocyte function . E2 influences food intake and eventually the maintenance of normal body weight in adult females. In female dogs, a phasic decrease in food intake occurs during estrus . Gradual decreases in eating through the follicular phase have been shown in monkeys, which show progressive increases in estrogens through the follicular phase comparable to those of humans . E2 treatment to OVX rats normalized meal size, food intake, and body weight gain to the levels observed in intact rats [19, 70]. ER is involved in the anorectic action of E2. Blockade of ER inhibits the effects of E2 on food intake, body weight gain, and fat accumulation in OVX rats . In contrast, Heine et al.  and D’Eon et al.  suggested that E2 decreases adiposity and adipocyte size in OVX mice independent of differences in energy intake, possibly through promoting fat oxidation and enhancing triglyceride breakdown [16, 67].
In addition to food intake and body weight regulation, estrogen improves glucose homeostasis and diabetes mellitus. Mice that lack ER have insulin resistance and impaired glucose tolerance . Both male and female aromatase-KO mice have reduced glucose oxidation, and male aromatase-KO mice develop glucose and insulin resistance that can be reversed by E2 treatment [58, 66]. ER and ER modulate glucose transporter 4 expression and stimulate glucose uptake in skeletal muscle of mice . Estrogens have also been shown to regulate vascular disease. Premenopausal women have a lower tendency to develop hypertension than do men of similar age, but the prevalence of CVD increases more rapidly in aging women than in men . The increased incidence of CVD in aged women may be due to the development of obesity. Although the rate of increase of CVD is greater at the postmenopausal age in women than at the same age in men, the actual incidence of CVD is still less in women than in men if hypertension is not included (Framington Heart Study). Thus, estrogen signaling through ERs leads to improvement of metabolic disorders.
As mentioned above, both PPAR and ERs have similar structures, action mechanisms, and functions, suggesting the interaction of PPAR with ERs in the control of these metabolic diseases including obesity. However, signal cross-talk between PPAR and ERs in the regulation of obesity is not clear.
3. PPAR Functions on Obesity
Over the last several decades, a number of studies have been published on the physiology, pharmacology, and functional genomics of PPAR In vivo and in vitro studies demonstrate that PPAR plays a central role in lipid and lipoprotein metabolism, and thereby decreases dyslipidemia associated with metabolic syndrome. Obesity is the leading cause for the development of metabolic diseases, such as obesity, type 2 diabetes, dyslipidemia, and CVD. There are important sex differences in the prevalence of obesity-related metabolic diseases [33, 73–75]. Ovarian hormones seem to have protective roles in metabolic diseases since women with functioning ovaries have much fewer incidences of such disorders, but these metabolic diseases dramatically increase in postmenopausal women.
3.1. Fenofibrate Regulates Obesity with Sexual Dimorphism
PPAR activator fenofibrate differentially influences body weight and adiposity in both sexes of mice. Fenofibrate improves body weight gain and adiposity in high fat-diet-fed male mice, but fails to regulate them in female mice (Figure 4) . In males, body weight and WAT mass increased by 44% and 77%, respectively, after 14-week administration of high fat diet. These parameters were lowered after fenofibrate treatment, more so than those of mice given a low fat diet, and the reduction in body weight correlated with a fall in adipose tissue mass. In contrast to males, fenofibrate slightly increased high fat diet-induced body weight and adipose tissue mass in female mice, suggesting a different PPAR action on females than on males in the control of obesity. Previous studies showed that fenofibrate can modulate body weight and adiposity in several animal models [9–11]. Since these results were obtained from males, fenofibrate may be an effective regulator of energy homeostasis in the male animal system. Taken together, these studies show that body weight gain and adipose tissue mass of male C57BL/6 mice were significantly reduced by fenofibrate, but those of females were not, and indicate that the action of fenofibrate on body weight and adiposity is different, depending on sex.
Although fibrates are drugs widely used to lower elevated plasma triglycerides and cholesterol, fenofibrate is shown to control lipid metabolism with sexual dimorphism. Serum concentrations of total cholesterol and triglycerides were significantly reduced by fenofibrate in male mice, similar to the previous reports [76, 77]. However, fenofibrate not only failed to decrease total cholesterol, but also decreased circulating level of triglycerides in female mice to a much lower extent than in similarly treated males. Based on the information that lipids accumulated in the adipose tissue are largely derived from circulating triglycerides, differential regulation of adiposity by fenofibrate is partly due to different levels of circulating lipids between sexes.
The regulatory effect of fenofibrate on obesity is not mediated through leptin since PPAR-knockout mice that become obese with age are not hyperphagic [8, 10]. Instead, many reports indicate that fenofibrate-regulated increases in hepatic -oxidation are involved in this process. FA oxidation results in a decrease in FAs available for triglyceride synthesis [78, 79]. According to Yoon et al. , fenofibrate elevated the transcriptional activation of PPARα target genes, acyl-CoA oxidase (ACOX), enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase (HD), and thiolase in both sexes of mice . However, the expression levels were much higher in males than in females, suggesting that fenofibrate exhibits sexually dimorphic activation of PPAR actions on hepatic -oxidation, resulting in the differential energy balance with sex.
Mancini et al.  and Guerre-Millo et al.  report that fenofibrate improves obesity due to its action on FA -oxidation in the liver and seems to act as a weight-stabilizer through its effect on liver metabolism [10, 11]. Moreover, the body weights of PPAR-deficient mice were greater than those of wild-type mice, and a marked increased amount of intra-abdominal adipose tissue was seen in PPAR-KO mice. In addition, Costet et al.  suggested the involvement of PPAR with a sexually dimorphic control of circulating lipids, fat storage, and obesity, in a study using male and female PPAR-null mice . In contrast to these investigators, Akiyama et al.  provided evidence that PPAR regulates lipid metabolism but is not associated with obesity . Similar to the results of Akiyama et al. , Yoon et al.  provided evidence that fenofibrate is involved in obesity, but not likely to have an effect on obesity mainly through PPAR-mediated action since it increases FA -oxidation and decreases serum triglycerides in female mice, although their effects are much lower compared with males .
Overall, fenofibrate treatment affects body weight, adipose tissue mass, lipid metabolism, and hepatic -oxidation with sexual dimorphism, but fenofibrate-regulated obesity is not directly associated with PPAR-mediated action and may be influenced by sex-related factors.
3.2. Fenofibrate Improves Male Obesity
Fenofibrate seems to suppress diet-induced obesity and severe hypertriglyceridemia caused by LDL receptor (LDLR) deficiency in male mice. The loss of LDLR increases susceptibility to diet-induced obesity and hypertriglyceridemia. Body weights and WAT mass increased in LDLR-null mice on a high fat diet compared with low fat diet controls [22, 81]. However, fenofibrate prevented the high fat diet-induced increases in body weight and WAT mass in male LDLR-null mice. The body weights of male LDLR-null mice were significantly reduced after 1 week of fenofibrate administration whereas wild-type mice showed weight decreases after 7 weeks of fenofibrate [20, 22], indicating that fenofibrate more effectively reduces body weight gain in LDLR-null mice than in wild-type mice. Interestingly, the final body weight of the fenofibrate-treated obese animals was very similar to that of lean animals on a lowfat diet. High fat diet-fed LDLR-null mice showed hepatic lipid accumulation, which was absent in the hepatocytes of mice on a low fat diet and which disappeared following fenofibrate treatment, mainly due to peroxisomal and mitochondrial β-oxidation of FAs [82, 83]. This indicates not only the prevention of body weight gain and the increased fat mobilization from WAT due to fenofibrate-induced increases of fat catabolism in the liver, but also a strong correlation between reduced body weight and decreased WAT mass by fenofibrate. In addition, fenofibrate did not affect food intake in high fat diet-induced obese LDLR-null mice. These results suggest that the increased liver activity may be paralleled by a large reduction in WAT mass, which accounts for most of the body weight reduction.
Fenofibrate also substantially decreased the increases in circulating triglycerides and total cholesterol levels, indicating that fenofibrate efficiently regulates triglyceride and cholesterol metabolism in male LDLR-null mice. Circulating triglyceride levels are thought to be regulated by the balance between its secretion and clearance. With lipoprotein catabolism suppressed, the increase in circulating triglycerides over time is indicative of the rate at which triglyceride is being secreted from the liver [84–86]. The hepatic triglyceride secretion rate was significantly lower in fenofibrate-treated mice when Triton WR1339 was used to prevent lipolysis. These observations suggest that the reduced circulating triglyceride levels after fenofibrate treatment are due to the decreased secretion of triglycerides from the liver.
The molecular mechanisms underlying the effects of fenofibrate on obesity and lipid metabolism involve the changes in the expression of apolipoprotein C-III (apo C-III) and ACOX. LDLR-null mice fed fenofibrate showed significantly lower mRNA levels of hepatic apo C-III, an apolipoprotein that limits tissue triglyceride clearance [87, 88]. Fenofibrate-activated PPAR in the liver increased mRNA levels of ACOX, the first and rate-limiting enzyme of PPAR-mediated FA -oxidation, which resulted in reduced triglyceride production .
In conclusion, fenofibrate prevents both obesity and hypertriglyceridemia through hepatic PPAR activation in male LDLR-deficient mice.
3.3. Fenofibrate Regulates Female Obesity Depending on the Presence of Ovaries
Based on the suggestion that fenofibrate inhibits body weight gain and adiposity in male LDLR-null mice, it can be hypothesized that fenofibrate improves obesity in female LDLR-null mice. Body weight gain and WAT mass were significantly increased in both female OVX and sham-operated (Sham) LDLR-null mice on a high fat diet for 8 weeks. The increases in body weight and WAT mass were higher in female OVX LDLR-null mice than in Sham mice. Interestingly, fenofibrate-treated female OVX LDLR-null mice had lower body weights and WAT mass, similar to those found in several animal models, while female Sham mice did not exhibit these fenofibrate-induced reductions . In db/db mice and fatty Zucker rats, the effect of fenofibrate on body weight depends on the utilization of FA, as demonstrated by a fenofibrate-induced increase of ACOX mRNA . PPAR-mediated FA -oxidation and hydrolysis of triglycerides by fenofibrate contribute to decreased body weight and WAT mass in OVX LDLR-null mice, suggesting that fenofibrate can act as a body weight-regulator in an animal model of postmenopausal women.
Serum triglycerides and total cholesterol were significantly increased in both female OVX and Sham LDLR-null mice. However, fenofibrate treatment substantially decreased high fat diet-induced increases of triglycerides and cholesterol in both female groups [9, 87]. In parallel with serum triglyceride levels, fenofibrate upregulated hepatic ACOX mRNA levels and downregulated apo C-III mRNA levels in both OVX and Sham LDLR-null mice [87, 88]. Such changes in mRNA levels of ACOX by fenofibrate were greater in female OVX LDLR-null mice than in Sham LDLR-null mice with functioning ovaries.
However, it is not likely that the PPAR-mediated reduction in serum triglycerides directly controls obesity in female Sham LDLR-null mice, which exhibited simultaneous decreases in serum triglycerides and increases in body weight and WAT mass. Thus, the effect of fenofibrate on the body weight of female Sham LDLR-null mice cannot be explained simply in terms of an altered and enhanced flux of FAs and triglycerides, since fenofibrate increased ACOX mRNA and decreased apo C-III gene expression in this group (although this expression was lower than in the OVX group). Moreover, these changes in ACOX and apo C-III mRNA did not correlate with increased body weight and adiposity. Such conflicting data suggest the possibility that this discordance may be caused by ovarian factors.
The regulation of obesity by fenofibrate in female wild-type C57BL/6J mice is similar to that in female LDLR-null mice. Fenofibrate reduced body weight gain and WAT mass in high fat diet-fed wild-type OVX mice but failed to do so in Sham mice (Figure 5(a)) . Body weights of OVX mice were found to be higher than those of Sham mice 6 weeks after commencing the high fat diet. Compared to high fat diet-fed OVX mice, fenofibrate-treated OVX mice had significantly decreased body weight gain by 6 weeks into the treatment regimen and had significantly lower body weight at 13 weeks. In addition to changes in body weight, WAT mass was significantly reduced after fenofibrate treatment, and the final WAT mass of the fenofibrate-treated OVX animals was lower than that of the OVX animals on a regular chow diet. In contrast to the OVX mice, fenofibrate did not decrease body weight gain and WAT mass increases in Sham mice. These results suggest that obesity is differentially affected by fenofibrate treatment in Sham and OVX mice.
Fenofibrate reportably acts as a weight-stabilizer through PPARα although these results were obtained using male animal models [9–11, 22]. Nevertheless, these reports suggest that fenofibrate not only prevents excessive weight gain but is also able to mobilize fat from adipose tissue by increasing fat catabolism in the liver. Notably, reductions in body weight gain and WAT mass by fenofibrate were similar in male and female OVX mice but were absent in female Sham mice.
Fenofibrate seems to differentially affect body weight and adiposity among OVX and Sham mice by a mechanism other than the modulation of leptin gene expression. Although leptin is produced only in adipose tissue and elicits satiety responses by binding to leptin receptors in the brain [89, 90], changes in leptin mRNA levels are in accordance with those in body weight and WAT mass in both female OVX and Sham mice following fenofibrate treatment. Consistent with this finding, Guerre-Millo et al.  reported that serum leptin concentrations positively correlated with body weight and epididymal adipose tissue mass in fenofibrate-treated male mice , suggesting that fenofibrate modulates body weight, not by influencing leptin gene expression and food intake, but by enhancing energy expenditure [91, 92].
Differences in PPAR target gene expression seem to explain the different effects of fenofibrate on gonad-dependent weight gain in females (Figure 5(b)). Fenofibrate not only elevated the transcriptional activation of PPAR target genes, ACOX, HD, and thiolase but also reduced apo C-III mRNA levels compared to a high fat diet alone in both groups of mice. Moreover, these alterations in expression levels were found to be more prominent in female OVX mice than in Sham mice after fenofibrate treatment. Thus, fenofibrate influences obesity via the differential activation of PPAR
It has also been reported that ovarian steroids can affect obesity and lipid metabolism and that these effects are likely mediated by estrogens . E2 insufficiency is thought to be largely responsible for increased adiposity and circulating lipids in OVX rodents because such animals do not display obesity, adiposity, and lipid disorders when they are administered E2 replacement [17–19]. Although the administration of E2 or fenofibrate alone effectively reduces body weight gain and WAT mass in high fat diet-fed female OVX mice, fenofibrate treatment does not prevent them in female Sham mice with functioning ovaries. These results suggest the possibility that signal cross-talk may exist between PPAR and ERs in their effects on obesity and that the action of fenofibrate may be influenced by estrogens in females [25, 27, 93].
In conclusion, treatment with fenofibrate has different effects on body weight and WAT mass due in part to differentially activating hepatic -oxidation and apo C-III gene expression between female Sham and OVX mice. These differences may provide important information about the mechanisms modulating obesity and about the actions of other lipid lowering drugs, such as fenofibrate, which are PPAR ligands in females.
3.4. The Actions of PPAR on Obesity Are Inhibited by Estrogens
My previous results show that the PPAR ligand fenofibrate reduced body weight gain and adiposity in male and female OVX mice, but not in female mice with functioning ovaries [20–23], suggesting that the actions of fenofibrate on obesity are influenced by E2.
E2 affects the ability of fenofibrate to reduce body weight gain and adiposity in female OVX mice. Mice fed a high fat diet with either fenofibrate or E2 for 13 weeks exhibited significant decreases in body weight gain and WAT mass compared to high fat diet-fed controls. These observations are supported by my previous results showing that fenofibrate stimulates hepatic FA -oxidation in female OVX mice [21, 23], as well as by other reports showing that E2 inhibits feeding by decreasing meal size in OVX animals [94, 95]. However, these reductions were not enhanced when mice were concomitantly treated with fenofibrate and E2, indicating that E2 may inhibit the function of PPAR in female obesity . Evidence from both humans and laboratory animals show that E2 plays an important role in regulating body weight and WAT mass. Ovariectomy in rodents increases WAT mass, and E2 replacement decreases WAT mass . Similarly, while postmenopausal women have increased body weight gain and WAT weight, E2 decreases both of these [96, 97]. Other studies have also suggested that fenofibrate reduces body weight gain in male animal models [9–11] but does not induce decreases in body weight and WAT mass gains in female mice [20, 21, 23], suggesting that E2 may inhibit the actions of fenofibrate on body weight and WAT mass in female OVX mice.
Similarly, the combination of E2 and fenofibrate did not result in any additional beneficial effects on lipid metabolism in female OVX mice. While serum levels of total cholesterol and triglycerides were lowered in mice fed a high fat diet with either fenofibrate or E2 compared with mice fed a high fat diet alone [9, 18], the combination of E2 and fenofibrate increased levels of circulating total cholesterol and triglycerides compared with either E2 or fenofibrate alone. These results are in agreement with findings that the combination of a lipid-lowering fibrate and hormone replacement therapy (HRT) for 3 months not only had no additional benefits on the routine serum lipid or lipoprotein profiles in overweight postmenopausal women with elevated triglycerides but also increased serum triglycerides . Consistent with the circulating lipid metabolism, the fenofibrate-induced decrease in hepatic lipid accumulation was also increased by E2 in female OVX mice. Mice fed a high fat diet showed considerable hepatic lipid accumulation, which was prevented by fenofibrate or E2. In contrast, mice concomitantly treated with fenofibrate and E2 showed an accumulation of triglyceride droplets. Thus, it appears that E2 inhibits fenofibrate-induced increases in fat catabolism in the liver of female OVX mice. Fenofibrate-treated OVX mice were found to have similar food intake to Sham controls whereas OVX mice given E2 showed decreased food intake. However, a combinational treatment of fenofibrate and E2 increased body weight gain, fat weight, and hepatic fat accumulation compared with fenofibrate alone, despite similar food consumption profiles between E2 and fenofibrate plus E2 groups, suggesting that E2 may affect the ability of fenofibrate to regulate energy balance.
Fenofibrate-activated PPARα has been shown to regulate the expression of a number of genes critical for FA -oxidation and lipid catabolism. Fenofibrate upregulated ACOX, HD, and thiolase mRNA levels whereas E2 downregulated the transcriptional activation of these genes. Coadministration of fenofibrate and E2 significantly decreased ACOX, HD, and thiolase mRNA levels compared with fenofibrate treatment. These results were in accordance with serum levels of triglycerides and total cholesterol as well as body weight and WAT mass. Thus, inhibition of the actions of PPAR on body weight, WAT mass, and circulating lipid levels by E2 may be attributed, in part, to reductions in hepatic mRNA expression of PPAR-mediated peroxisomal FA -oxidizing enzymes by E2.
Consistent with the in vivo data, E2 inhibited basal PPARα reporter gene activity as well as Wy14,643-induced reporter gene activation in NMu2Li murine liver cells transfected with PPAR showing that E2 can modulate PPAR transactivation (Figure 6(a)). The inhibitory activity by E2 is mediated through its binding to endogenous ERs that are normally expressed in NMu2Li liver cells since it is reported that E2 does not bind directly PPARs . However, the possibility that E2 directly binds to PPAR and inhibits PPAR function cannot be excluded, because no binding studies have been performed. In cells transfected with either ER or ER, ERs inhibited the basal expression of PPRE-mediated reporter gene activity (Figure 6(b)). These inhibitory effects were significantly increased by E2 treatment. This is supported by results showing that PPARs can regulate ER target gene expression and that signal cross-talk between ERs and PPARs has been reported to be bidirectional [24–26, 28, 93].
Mechanistic studies revealed that the E2-ER complex was not likely to be competent for PPAR transactivation, as indicated by the inability of E2 to stimulate PPAR recruitment of coactivators such as CBP (Figure 6(c)). Ligand-induced conformational changes that allow recruitment of coactivators, such as CBP and the dissociation of corepressors such as NCoR, are obligatory for transactivation by PPAR. Treatment of transfected CV-1 cells with Wy14,643 caused efficient CBP recruitment as evidenced by an increase in luciferase reporter gene activity. However, E2 significantly decreased Wy14,643-induced CBP association in the presence of ER or ER. Thus, inhibition of PPAR transactivation by ERs was due to competition for coactivators, increased availability of corepressors, or some other mechanism. [26, 28] It has previously been shown that competition of distinct nuclear receptor for coactivator binding results in a negative cross-talk between nuclear receptors [99, 100]. These results suggest that E2 inhibition of PPAR function occurs by impairing the recruitment of transcriptional coactivators.
PPAR and ERs bind to short DNA sequences termed HREs, ERE for ERs and PPRE for PPAR [54, 101]. An ERE is an inverted repeat containing three intervening bases (AGGTCA N3 TGACCT) whereas a PPRE is a direct repeat with one or two intervening sequences (AGGTCA N1,2 AGGTCA). Nonetheless, these sequences contain an AGGTCA half site, which could be recognized by either ERs or PPAR. Signal cross-talk between PPAR/RXR and ERs has been reported to occur through competitive binding to ERE . Therefore, the inhibition of PPAR transactivation by ERs may also have been due to their competition for PPRE.
In conclusion, in vivo and in vitro studies demonstrate that E2 inhibits the actions of PPAR on obesity through its effects on hepatic PPAR -dependent regulation of target genes and that these processes are mediated by inhibition of PPAR recruitment of coactivators by E2-activated ERs (Figure 7). PPAR ligands fibrates may act as efficient weight controllers under estrogen-free conditions. Although E2 alone decreases body weight gain and WAT mass, E2 may impair PPAR actions on obesity. Thus, these results provide a rationale for the use of fenofibrate in men and postmenopausal women with obesity and lipid disorder, but not for premenopausal women with functioning ovaries.
(a) Competition for coactivators
(b) Differential regulation of obesity
Obesity is the leading cause of the metabolic diseases including type 2 diabetes, atherosclerosis, and hypertension. PPAR has been the subject of intense academic and pharmaceutical research because of its ability to improve obesity-related metabolic disorders. The PPAR ligand fenofibrate seems to exhibit an antiobesity effect through FA -oxidation in animal models although such an effect of PPAR activators has not yet been reported in humans. However, this idea is supported by several human studies showing that obese patients with impaired fat oxidation failed to lose weight, suggesting that elevated fat oxidation leads to weight loss. Interestingly, there is a sex difference in the control of obesity by fenofibrate. Fenofibrate regulates body weight and adiposity with sexual dimorphism in nutritionally induced obese male mice. Moreover, fenofibrate-induced reductions in body weight gain and WAT mass in male mice were also shown by female OVX mice, but these effects were absent in female Sham mice, suggesting the involvement of ovarian hormones in the differential regulation of obesity among these groups. In OVX mice, E2 inhibited the actions of fenofibrate-activated PPAR on obesity, due in part to reductions in hepatic expression of PPAR-mediated FA -oxidizing enzymes by E2, a process mediated through the inhibition of PPAR coactivator recruitment by E2. These results provide a mechanism to explain why fenofibrate reduces body weight gain and adiposity in males and OVX female mice but does not regulate obesity in female mice with functioning ovaries.
This paper was supported by Mid-career Researcher Program (no. 2009-0083990) and Female Scientist Program (no. 2010-0017313) through NRF Grant funded by the MEST.
- I. Issemann and S. Green, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990.
- F. Beck, S. Plummer, P. V. Senior, S. Byrne, S. Green, and W. J. Brammar, “The ontogeny of peroxisome-proliferator-activated receptor gene expression in the mouse and rat,” Proceedings of the Royal Society B, vol. 247, no. 1319, pp. 83–87, 1992.
- O. Braissant, F. Foufelle, C. Scotto, M. Dauça, and W. Wahli, “Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996.
- T. Aoyama, J. M. Peters, N. Iritani et al., “Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α (PPARα),” Journal of Biological Chemistry, vol. 273, no. 10, pp. 5678–5684, 1998.
- J. Auwerx, K. Schoonjans, J.-C. Fruchart, and B. Staels, “Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR,” Atherosclerosis, vol. 124, supplement, pp. S29–S37, 1996.
- R. Hertz, J. Bishara-Shieban, and J. Bar-Tana, “Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III,” Journal of Biological Chemistry, vol. 270, no. 22, pp. 13470–13475, 1995.
- Z. H. Yan, W. G. Karam, J. L. Staudinger, A. Medvedev, B. I. Ghanayem, and A. M. Jetten, “Regulation of peroxisome proliferator-activated receptor α-induced transactivation by the nuclear orphan receptor TAK1/TR4,” Journal of Biological Chemistry, vol. 273, no. 18, pp. 10948–10957, 1998.
- P. Costet, C. Legendre, J. Moré, A. Edgar, P. Galtier, and T. Pineau, “Peroxisome proliferator-activated receptor α-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis,” Journal of Biological Chemistry, vol. 273, no. 45, pp. 29577–29585, 1998.
- E. Chaput, R. Saladin, M. Silvestre, and A. D. Edgar, “Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight,” Biochemical and Biophysical Research Communications, vol. 271, no. 2, pp. 445–450, 2000.
- M. Guerre-Millo, P. Gervois, E. Raspé et al., “Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity,” Journal of Biological Chemistry, vol. 275, no. 22, pp. 16638–16642, 2000.
- F. P. Mancini, A. Lanni, L. Sabatino et al., “Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats,” FEBS Letters, vol. 491, no. 1-2, pp. 154–158, 2001.
- P. Mystkowski and M. W. Schwartz, “Gonadal steroids and energy homeostasis in the leptin era,” Nutrition, vol. 16, no. 10, pp. 937–946, 2000.
- G. N. Wade, “Some effects of ovarian hormones on food intake and body weight in female rats,” Journal of Comparative and Physiological Psychology, vol. 88, no. 1, pp. 183–193, 1975.
- A. Tchernof, J. Calles-Escandon, C. K. Sites, and E. T. Poehlman, “Menopause, central body fatness, and insulin resistance: effects of hormone-replacement therapy,” Coronary Artery Disease, vol. 9, no. 8, pp. 503–511, 1998.
- N. Geary and L. Asarian, “Estradiol increases glucagon's satiating potency in ovariectomized rats,” American Journal of Physiology, vol. 281, no. 4, pp. R1290–R1294, 2001.
- T. M. D'Eon, S. C. Souza, M. Aronovitz, M. S. Obin, S. K. Fried, and A. S. Greenberg, “Estrogen regulation of adiposity and fuel partitioning: evidence of genomic and non-genomic regulation of lipogenic and oxidative pathways,” Journal of Biological Chemistry, vol. 280, no. 43, pp. 35983–35991, 2005.
- G. C. Shearer, J. A. Joles, H. Jones Jr., R. L. Walzem, and G. A. Kaysen, “Estrogen effects on triglyceride metabolism in analbuminemic rats,” Kidney International, vol. 57, no. 6, pp. 2268–2274, 2000.
- M. Shinoda, M. G. Latour, and J.-M. Lavoie, “Effects of physical training on body composition and organ weights in ovariectomized and hyperestrogenic rats,” International Journal of Obesity, vol. 26, no. 3, pp. 335–343, 2002.
- D. M. Roesch, “Effects of selective estrogen receptor agonists on food intake and body weight gain in rats,” Physiology & Behavior, vol. 87, no. 1, pp. 39–44, 2006.
- M. Yoon, S. Jeong, C. J. Nicol et al., “Fenofibrate regulates obesity and lipid metabolism with sexual dimorphism,” Experimental and Molecular Medicine, vol. 34, no. 6, pp. 481–488, 2002.
- M. Yoon, S. Jeong, H. Lee et al., “Fenofibrate improves lipid metabolism and obesity in ovariectomized LDL receptor-null mice,” Biochemical and Biophysical Research Communications, vol. 302, no. 1, pp. 29–34, 2003.
- S. Jeong, M. Kim, M. Han et al., “Fenofibrate prevents obesity and hypertriglyceridemia in low-ddensity lipoprotein receptor-null mice,” Metabolism, vol. 53, no. 5, pp. 607–613, 2004.
- S. Jeong, M. Han, H. Lee et al., “Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice,” Metabolism, vol. 53, no. 10, pp. 1284–1289, 2004.
- H. Keller, F. Givel, M. Perroud, and W. Wahli, “Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements,” Molecular Endocrinology, vol. 9, no. 7, pp. 794–804, 1995.
- S. B. Nunez, J. A. Medin, H. Keller, K. Ozato, W. Wahli, and J. Segars, “Retinoid X receptor β and peroxisome proliferator-activated receptor activate an estrogen response element,” Recent Progress in Hormone Research, vol. 50, no. 1, pp. 409–415, 1995.
- Y. Zhu, L. Kan, C. Qi et al., “Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP) as a coactivator for PPAR,” Journal of Biological Chemistry, vol. 275, no. 18, pp. 13510–13516, 2000.
- S. B. Nuñez, J. A. Medin, O. Braissant et al., “Retinoid X receptor and peroxisome proliferator-activated receptor activate an estrogen responsive gene independent of the estrogen receptor,” Molecular and Cellular Endocrinology, vol. 127, no. 1, pp. 27–40, 1997.
- I. Tcherepanova, P. Puigserver, J. D. Norris, B. M. Spiegelman, and D. P. McDonnell, “Modulation of estrogen receptor-α transcriptional activity by the coactivator PGC-1,” Journal of Biological Chemistry, vol. 275, no. 21, pp. 16302–16308, 2000.
- E. Boitier, J.-C. Gautier, and R. Roberts, “Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: relevance for human health and disease,” Comparative Hepatology, vol. 2, article 3, 2003.
- M. E. Wierman, “Sex steroid effects at target tissues: mechanisms of action,” Advances in Physiology Education, vol. 31, no. 1, pp. 26–33, 2007.
- D. L. Bain, A. F. Heneghan, K. D. Connaghan-Jones, and M. T. Miura, “Nuclear receptor structure: implications for function,” Annual Review of Physiology, vol. 69, pp. 201–220, 2007.
- S. Jeong and M. Yoon, “Inhibition of the actions of peroxisome proliferator-activated receptor a on obesity by estrogen,” Obesity, vol. 15, no. 6, pp. 1430–1440, 2007.
- M. Yoon, “The role of PPARα in lipid metabolism and obesity: focusing on the effects of estrogen on PPARα actions,” Pharmacological Research, vol. 60, pp. 151–159, 2009.
- G. Jenster, “Coactivators and corepressors as mediators of nuclear receptor function: an update,” Molecular and Cellular Endocrinology, vol. 143, no. 1-2, pp. 1–7, 1998.
- C. K. Glass, “Going nuclear in metabolic and cardiovascular disease,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 556–560, 2006.
- F. Flamant, K. Gauthier, and J. Samarut, “Thyroid hormones signaling is getting more complex: STORMs are coming,” Molecular Endocrinology, vol. 21, no. 2, pp. 321–333, 2007.
- G. Arpino, L. Wiechmann, C. K. Osborne, and R. Schiff, “Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance,” Endocrine Reviews, vol. 29, no. 2, pp. 217–233, 2008.
- T. Sher, H.-F. Yi, O. W. McBride, and F. J. Gonzalez, “cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor,” Biochemistry, vol. 32, no. 21, pp. 5598–5604, 1993.
- N. Marx, H. Duez, J.-C. Fruchart, and B. Staels, “Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells,” Circulation Research, vol. 94, no. 9, pp. 1168–1178, 2004.
- B. Staels, W. Koenig, A. Habib et al., “Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators,” Nature, vol. 393, no. 6687, pp. 790–793, 1998.
- G. Krey, O. Braissant, F. L'Horset et al., “Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay,” Molecular Endocrinology, vol. 11, no. 6, pp. 779–791, 1997.
- J. P. Berger, T. E. Akiyama, and P. T. Meinke, “PPARs: therapeutic targets for metabolic disease,” Trends in Pharmacological Sciences, vol. 26, no. 5, pp. 244–251, 2005.
- C. Fiévet, J.-C. Fruchart, and B. Staels, “PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome,” Current Opinion in Pharmacology, vol. 6, no. 6, pp. 606–614, 2006.
- R. A. K. Srivastava, R. Jahagirdar, S. Azhar, S. Sharma, and C. L. Bisgaier, “Peroxisome proliferator-activated receptor-α selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice,” Molecular and Cellular Biochemistry, vol. 285, no. 1-2, pp. 35–50, 2006.
- S. Wang, A. Subramaniam, M. A. Cawthorne, and J. C. Clapham, “Increased fatty acid oxidation in transgenic mice overexpressing UCP3 in skeletal muscle,” Diabetes, Obesity and Metabolism, vol. 5, no. 5, pp. 295–301, 2003.
- À. Cabrero, M. Alegret, R. M. Sánchez, T. Adzet, J. C. Laguna, and M. Vázquez, “Bezafibrate reduces mRNA levels of adipocyte markers and increases fatty acid oxidation in primary culture of adipocytes,” Diabetes, vol. 50, no. 8, pp. 1883–1890, 2001.
- Y. Okamoto, H. Higashiyama, H. Inoue, M. Kanematsu, M. Kinoshita, and S. Asano, “Quantitative image analysis in adipose tissue using an automated image analysis system: differential effects of peroxisome proliferator-activated receptor-α and -γ agonist on white and brown adipose tissue morphology in AKR obese and db/db diabetic mice,” Pathology International, vol. 57, no. 6, pp. 369–377, 2007.
- S. Jeong and M. Yoon, “Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARα in high fat diet-induced obese mice,” Experimental and Molecular Medicine, vol. 41, no. 6, pp. 397–405, 2009.
- D. M. Muoio and G. L. Dohm, “Peripheral metabolic actions of leptin,” Best Practice & Research: Clinical Endocrinology & Metabolism, vol. 16, no. 4, pp. 653–666, 2002.
- E. P. Hines, S. S. White, J. P. Stanko, E. A. Gibbs-Flournoy, C. Lau, and S. E. Fenton, “Phenotypic dichotomy following developmental exposure to perfluorooctanoic acid (PFOA) in female CD-1 mice: low doses induce elevated serum leptin and insulin, and overweight in mid-life,” Molecular and Cellular Endocrinology, vol. 304, no. 1-2, pp. 97–105, 2009.
- E. H. Koh, M.-S. Kim, J.-Y. Park et al., “Peroxisome proliferator-activated receptor (PPAR)-α activation prevents diabetes in OLETF rats: comparison with PPAR-γ activation,” Diabetes, vol. 52, no. 9, pp. 2331–2337, 2003.
- F. Lalloyer, B. Vandewalle, F. Percevault et al., “Peroxisome proliferator-activated receptor α improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets,” Diabetes, vol. 55, no. 6, pp. 1605–1613, 2006.
- B. Staels, M. Maes, and A. Zambon, “Fibrates and future PPARα agonists in the treatment of cardiovascular disease,” Nature Clinical Practice Cardiovascular Medicine, vol. 5, no. 9, pp. 542–553, 2008.
- L. Klein-Hitpass, M. Schorpp, U. Wagner, and G. U. Ryffel, “An estrogen-responsive element derived from the 5' flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells,” Cell, vol. 46, no. 7, pp. 1053–1061, 1986.
- J. M. Hall and D. P. McDonnel, “The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens,” Endocrinology, vol. 140, no. 12, pp. 5566–5578, 1999.
- B. S. Katzenellenbogen, “Estrogen receptors: bioactivities and interactions with cell signaling pathways,” Biology of Reproduction, vol. 54, no. 2, pp. 287–293, 1996.
- M. N. Dieudonné, M. C. Leneveu, Y. Giudicelli, and R. Pecquery, “Evidence for functional estrogen receptors α and β in human adipose cells: regional specificities and regulation by estrogens,” American Journal of Physiology, vol. 286, no. 3, pp. C655–C661, 2004.
- R. P. A. Barros, U. F. Machado, M. Warner, and J.-Å. Gustafsson, “Muscle GLUT4 regulation by estrogen receptors ERβ and ERα,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 5, pp. 1605–1608, 2006.
- K. F. Koehler, L. A. Helguero, L.-A. Haldosén, M. Warner, and J.-Å. Gustafsson, “Reflections on the discovery and significance of estrogen receptor β,” Endocrine Reviews, vol. 26, no. 3, pp. 465–478, 2005.
- A. Wiik, B. Glenmark, M. Ekman et al., “Oestrogen receptor β is expressed in adult human skeletal muscle both at the mRNA and protein level,” Acta Physiologica Scandinavica, vol. 179, no. 4, pp. 381–387, 2003.
- S. Nilsson, S. Mäkelä, E. Treuter et al., “Mechanisms of estrogen action,” Physiological Reviews, vol. 81, no. 4, pp. 1535–1565, 2001.
- C. Bouchard, J.-P. Després, and P. Mauriège, “Genetic and nongenetic determinants of regional fat distribution,” Endocrine Reviews, vol. 14, no. 1, pp. 72–93, 1993.
- J. C. Sharp, J. C. Copps, Q. Liu et al., “Analysis of ovariectomy and estrogen effects on body composition in rats by X-ray and magnetic resonance imaging techniques,” Journal of Bone and Mineral Research, vol. 15, no. 1, pp. 138–146, 2000.
- J. M. Gray and G. N. Wade, “Food intake, body weight, and adiposity in female rats: actions and interactions of progestins and antiestrogens,” American Journal of Physiology, vol. 240, no. 5, pp. E474–E481, 1981.
- A. Leshner and G. Collier, “The effects of gonadectomy on the sex differences in dietary self selection patterns and carcass compositions of rats,” Physiology & Behavior, vol. 11, no. 5, pp. 671–676, 1973.
- M. E. E. Jones, A. W. Thorburn, K. L. Britt et al., “Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 23, pp. 12735–12740, 2000.
- P. A. Heine, J. A. Taylor, G. A. Iwamoto, D. B. Lubahn, and P. S. Cooke, “Increased adipose tissue in male and female estrogen receptor-α knockout mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 23, pp. 12729–12734, 2000.
- K. A. Houpt, B. Coren, H. F. Hintz, and J. E. Hilderbrant, “Effect of sex and reproductive status on sucrose preference, food intake, and body weight of dogs,” Journal of the American Veterinary Medical Association, vol. 174, no. 10, pp. 1083–1085, 1979.
- H. Rosenblatt, I. Dyrenfurth, M. Ferin, and R. L. vande Wiele, “Food intake and the menstrual cycle in rhesus monkeys,” Physiology & Behavior, vol. 24, no. 3, pp. 447–449, 1980.
- N. Geary and L. Asarian, “Cyclic estradiol treatment normalizes body weight and test meal size in ovariectomized rats,” Physiology & Behavior, vol. 67, no. 1, pp. 141–147, 1999.
- Y.-Q. Liang, M. Akishita, S. Kim et al., “Estrogen receptor β is involved in the anorectic action of estrogen,” International Journal of Obesity and Related Metabolic Disorders, vol. 26, no. 8, pp. 1103–1109, 2002.
- C. Gasse, H.-W. Hense, J. Stieber, A. Döring, A. D. Liese, and U. Keil, “Assessing hypertension management in the community: trends of prevalence, detection, treatment, and control of hypertension in the MONICA Project, Augsburg 1984–1995,” Journal of Human Hypertension, vol. 15, no. 1, pp. 27–36, 2001.
- R. P. A. Barros, U. F. Machado, and J.-A. Gustafsson, “Estrogen receptors: new players in diabetes mellitus,” Trends in Molecular Medicine, vol. 12, no. 9, pp. 425–431, 2006.
- V. Regitz-Zagrosek, E. Lehmkuhl, and S. Mahmoodzadeh, “Gender aspects of the role of the metabolic syndrome as a risk factor for cardiovascular disease,” Gender Medicine, vol. 4, supplement B, pp. S162–S177, 2007.
- H. Shi and D. J. Clegg, “Sex differences in the regulation of body weight,” Physiology & Behavior, vol. 97, pp. 199–204, 2009.
- J. C. Fruchart, H. B. Brewer Jr., E. Leitersdorf et al., “Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease,” American Journal of Cardiology, vol. 81, no. 7, pp. 912–917, 1998.
- P. J. Lupien, D. Brun, C. Gagne, S. Moorjani, P. Bielman, and P. Julien, “Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins,” Canadian Journal of Cardiology, vol. 7, no. 1, pp. 27–33, 1991.
- A. C. Rustan, E. N. Christiansen, and C. A. Drevon, “Serum lipids, hepatic glycerolipid metabolism and peroxisomal fatty acid oxidation in rats fed ω-3 and ω-6 fatty acids,” Biochemical Journal, vol. 283, no. 2, pp. 333–339, 1992.
- S. Skrede, J. Bremer, R. K. Berge, and A. C. Rustan, “Stimulation of fatty acid oxidation by a 3-thia fatty acid reduces triacylglycerol secretion in cultured rat hepatocytes,” Journal of Lipid Research, vol. 35, no. 8, pp. 1395–1404, 1994.
- T. E. Akiyama, C. J. Nicol, C. Fievet et al., “Peroxisome proliferator-activated receptor-α regulates lipid homeostasis, but is not associated with obesity. Studies with congenic mouse lines,” Journal of Biological Chemistry, vol. 276, no. 42, pp. 39088–39093, 2001.
- S. A. Schreyer, C. Vick, T. C. Lystig, P. Mystkowski, and R. C. LeBoeuf, “LDL receptor but not apolipoprotein E deficiency increases diet-induced obesity and diabetes in mice,” American Journal of Physiology, vol. 282, pp. E207–E214, 2002.
- B. G. Lake, “Mechanisms of hepatocarcinogenicity of peroxisome-proliferating drugs and chemicals,” Annual Review of Pharmacology and Toxicology, vol. 35, pp. 483–507, 1995.
- A. Minnich, N. Tian, L. Byan, and G. Bilder, “A potent PPARα agonist stimulates mitochondrial fatty acid β-oxidation in liver and skeletal muscle,” American Journal of Physiology, vol. 280, no. 2, pp. E270–E279, 2001.
- C. Taghibiglou, A. Carpentier, S. C. Van Iderstine et al., “Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model,” Journal of Biological Chemistry, vol. 275, no. 12, pp. 8416–8425, 2000.
- P. Siri, N. Candela, Y.-L. Zhang et al., “Post-transcriptional stimulation of the assembly and secretion of triglyceride-rich apolipoprotein B lipoproteins in a mouse with selective deficiency of brown adipose tissue, obesity, and insulin resistance,” Journal of Biological Chemistry, vol. 276, no. 49, pp. 46064–46072, 2001.
- T. Shimizugawa, M. Ono, M. Shimamura et al., “ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase,” Journal of Biological Chemistry, vol. 277, no. 37, pp. 33742–33748, 2002.
- J. M. Peters, N. Hennuyer, B. Staels et al., “Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor α-deficient mice,” Journal of Biological Chemistry, vol. 272, no. 43, pp. 27307–27312, 1997.
- B. Staels, N. Vu-Dac, V. A. Kosykh et al., “Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates,” Journal of Clinical Investigation, vol. 95, no. 2, pp. 705–712, 1995.
- Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold, and J. M. Friedman, “Positional cloning of the mouse obese gene and its human homologue,” Nature, vol. 372, no. 6505, pp. 425–432, 1994.
- G.-H. Lee, R. Proenca, J. M. Montez et al., “Abnormal splicing of the leptin receptor in diabetic mice,” Nature, vol. 379, no. 6566, pp. 632–635, 1996.
- L. J. Kelly, P. P. Vicario, G. M. Thompson et al., “Peroxisome proliferator-activated receptors γ and α mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression,” Endocrinology, vol. 139, no. 12, pp. 4920–4927, 1998.
- N. Tsuboyama-Kasaoka, M. Takahashi, H. Kim, and O. Ezaki, “Up-regulation of liver uncoupling protein-2 mRNA by either fish oil feeding or fibrate administration in mice,” Biochemical and Biophysical Research Communications, vol. 257, no. 3, pp. 879–885, 1999.
- X. Wang and M. W. Kilgore, “Signal cross-talk between estrogen receptor alpha and beta and the peroxisome proliferator-activated receptor gamma1 in MDA-MB-231 and MCF-7 breast cancer cells,” Molecular and Cellular Endocrinology, vol. 194, no. 1-2, pp. 123–133, 2002.
- G. N. Wade, J. M. Gray, and T. J. Bartness, “Gonadal influences on adiposity,” International Journal of Obesity, vol. 9, no. 1, pp. 83–92, 1985.
- L. Asarian and N. Geary, “Modulation of appetite by gonadal steroid hormones,” Philosophical Transactions of the Royal Society of London. Series B, vol. 361, no. 1471, pp. 1251–1263, 2006.
- A. Tchernof, J. Calles-Escandon, C. K. Sites, and E. T. Poehlman, “Menopause, central body fatness, and insulin resistance: effects of hormone-replacement therapy,” Coronary Artery Disease, vol. 9, no. 8, pp. 503–511, 1998.
- C. Nerbrand, P. Nyberg, L. Nordström, and G. Samsioe, “Effects of a lipid lowering fibrate and hormone replacement therapy on serum lipids and lipoproteins in overweight postmenopausal women with elevated triglycerides,” Maturitas, vol. 42, no. 1, pp. 55–62, 2002.
- H. Ma, H. W. Sprecher, and P. E. Kolattukudy, “Estrogen-induced production of a peroxisome proliferator-activated receptor (PPAR) ligand in a PPARγ-expressing tissue,” Journal of Biological Chemistry, vol. 273, no. 46, pp. 30131–30138, 1998.
- G. N. Lopez, P. Webb, J. H. Shinsako, J. D. Baxter, G. L. Greene, and P. J. Kushner, “Titration by estrogen receptor activation function-2 of targets that are downstream from coactivators,” Molecular Endocrinology, vol. 13, no. 6, pp. 897–909, 1999.
- A. Foryst-Ludwig, M. Clemenz, S. Hohmann et al., “Metabolic actions of estrogen receptor beta (ERβ) are mediated by a negative cross-talk with PPARγ,” PLoS Genetics, vol. 4, no. 6, Article ID e1000108, 2008.
- J. D. Tugwood, I. Issemann, R. G. Anderson, K. R. Bundell, W. L. McPheat, and S. Green, “The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene,” The EMBO Journal, vol. 11, no. 2, pp. 433–439, 1992.
Copyright © 2010 Michung Yoon. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.